DNA Vaccine Developer Inovio Pharmaceuticals (INO) is Currently Having an Investment Conference
H.C. Wainwright Global Investment Conference, September 12-14, 2022
In my continuing efforts to learn more about how the Vaccine Sausage gets made, I am now exploring investment conferences.
I’m not a professional investor or…an investor…so if anyone has any good insights, please feel free to weigh in and provide expertise.
But it’s fun to see the industry players put on their Sunday best and trot out their sales pitches.
Here is one company that I stumbled upon, Inovio, who specialize in DNA technology and boasts an interesting proprietary product, their Cellectra device, which is like a transdermal gene applicator of sorts.
From a Summer, 2020, Press Release:
INOVIO has created DNA-encoded monoclonal antibodies (dMAbs) that we believe may overcome many of the limitations associated with conventional mAb technology:
Using our core DNA medicines technology, we encode the DNA sequence for a specific monoclonal antibody in a DNA plasmid. We deliver the plasmid directly into cells of the body using our investigational CELLECTRA device, enabling these cells to manufacture the mAbs in vivo – unlike conventional mAb technology that requires manufacture outside of the body.
This approach provides potential advantages in terms of lower production costs, as well as the ability to target a pharmacokinetic profile that provides control in terms of dosing regimen, peak responses, duration of responses, and toxicity.
Additional potential advantages include faster and easier engineering and construction of the newest mAb-related biologics, such as bispecific T Cell Antibodies (dBTAs)
Inovio is having a conference right now, today! to pitch their wares to investors.
Power points are linked if you wish to click through to the whole series.
*proprietary smart device, this must be the CELLECTRA device.
We are still marching on with this COVID-19 Vaccine Candidate angle in 2022, it would seem.
The next several slides highlight various Vaccines and cancer treatment technologies. I’ll only show the first.
Going back in time a bit.
The Intradermal Device for Vaccines was highlighted in this June 23, 2020, Press Release, as Inovio received $71m from the Dept. of Defense, and $5m give or take from the Bill and Melinda Gates Foundation.
This was Peak Covid Warp Speed time.
*Is it odd that the DOD is never far behind when it comes to…vaccines?
I wonder if the transdermal gene application would have kept the payload in the lymph node area and not let it circulate to the ovaries and liver and testes?
Also, did we ever really need a vaccine for Covid?
Do we still need one…now?
2020 press release is linked to pic.
- U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine
- INOVIO to report on interim U.S. Phase 1 clinical trial results in late June
- INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer
PLYMOUTH MEETING, Pa., June 23, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has received $71 million funding from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the company's proprietary CELLECTRA® 3PSP smart device and the procurement of CELLECTRA® 2000 devices, which are used to deliver INO-4800 directly into the skin.® 3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to drive a robust immune response. Interim results of U.S. Phase 1 clinical studies of INO-4800 will be available later this month. A Phase 2/3 efficacy trial is planned to begin this summer (July/August).
The DoD contract, from the JPEO-CRBND-EB through funding provided by the Defense Health Program, builds upon two separate prior $5 million grants from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI), to accelerate the testing of CELLECTRA® 3PSP. Initial development of this next generation CELLECTRA® 3PSP smart device began in 2019 with $8.1 million in funding from the medical arm of the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium.
Dr. J. Joseph Kim, INOVIO's President and CEO, said, "INOVIO is very pleased to receive this significant funding from the U.S. Department of Defense to continue our rapid scale-up capacity for our breakthrough DNA medicines delivery device CELLECTRA®. We look forward to working closely with DoD, JPEO-CBRND and JPL-CBRND-EB to provide much needed protection to DoD personnel and their families through development of a safe and effective vaccine against COVID-19. This next generation smart device leverages the efficacy delivery and safety track record of an earlier version that has received CE mark certification and has been used in clinical trials to safely dose more than 2,000 patients in over 7,000 administrations of INOVIO's DNA medicines. The current DoD contract further supports INOVIO's large-scale production of devices and arrays to deliver potentially hundreds of millions of doses of INO-4800 next year to combat the global COVID-19 pandemic."
My big takeaway is that COVID-19 Vaccine Technology is still being pumped as a growth market.
Not sure what to do with that. 🤔